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Ubiquitin proteasome system (UPS) dysfunction has been implicated in the development of many neuronal disorders, including
Parkinson’s disease (PD). Previous studies focused on individual neuroprotective agents and their respective abilities to prevent
neurotoxicity following a variety of toxic insults. However, the effects of the antioxidant N-acetylcysteine (NAC) on proteasome
impairment-induced apoptosis have not been well characterized in human neuronal cells. The aim of this study was to
determine whether cotreatment of NAC and insulin-like growth factor-1 (IGF-1) efficiently protected against proteasome inhibitorinduced cytotoxicity in SH-SY5Y cells. Our results demonstrate that the proteasome inhibitor, MG132, initiates poly(ADP-ribose)
polymerase (PARP) cleavage, caspase 3 activation, and nuclear condensation and fragmentation. In addition, MG132 treatment leads
to endoplasmic reticulum (ER) stress and autophagy-mediated cell death. All of these events can be attenuated without obvious
reduction of MG132 induced protein ubiquitination by first treating the cells with NAC and IGF-1 separately or simultaneously prior
to exposure to MG132. Moreover, our data demonstrated that the combination of the two proved to be significantly more effective for
neuronal protection. Therefore, we conclude that the simultaneous use of growth/neurotrophic factors and a free radical scavenger
may increase overall protection against UPS dysfunction-mediated cytotoxicity and neurodegeneration.

1. Introduction
In both sporadic and familial Parkinson’s disease (PD), pathways leading to neuronal death are driven mainly by two key
pathological events: aberrant protein homeostasis, including
aggregation of proteins that normally would be disposed by
the UPS system, and mitochondrial alterations secondary
to proteinopathy-associated aggregation, which result from
obligate mitochondrial Ca++ loading in response to this
aggregation [1, 2]. A growing body of evidence implicates
oxidative stress as an important intersection point between
these two events [3]. Neurons are particularly vulnerable to
proteinopathy (including abnormal aggregation of proteins)
because of their long life span [4]. Death of dopaminergic
neurons and accumulation of eosinophilic inclusions termed
as Lewy bodies (LBs) in the substantia nigra pars compacta
and other brain stem nuclei are the main pathological

characteristics of PD [5]. During the development of PD,
cellular defense mechanisms including antioxidants, the
unfolded protein response (UPR), molecular chaperons, the
ubiquitin-protease system (UPS), and autophagy are severely
compromised [6]. Each of these defense systems offers therapeutic targets for intervention in the mechanism for their
initiation and progression in the neurons.
In neurons, two particular protein clearance routes,
the UPS and the autophagy pathways, are critical for the
maintenance of cellular homeostasis, including ATP balance,
amino-acid recycling, and protein quality control. Of these
two mechanisms, UPS degradation of abnormal proteins
is more important. The UPS process operates following
“tagging” of abnormal proteins with ubiquitin, which in turn
targets the tagged proteins to the proteasome for degradation
[7]. However, treatment of cultured neurons with agents
that cause proteasome inhibition results in compensatory
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autophagy, thereby preventing protein accumulation and
cytotoxicity [7]. This suggests that clearance of proteins by the
autophagy route correlates with their propensity to aggregate
[8].
The LBs in substantia nigra neurons of PD patients are
composed of a protein called 𝛼-synuclein, which is a substrate
both for UPS degradation and for autophagy [7, 9]. Although
neuronal autophagy appears primarily to be a protective
process in the nervous system, it can also play a role in
neuronal death because there is a limit to the number of
autophagic vesicles (and their contained protein) that an
individual cell can handle [8, 10].
The proteasome inhibitor MG132 (Carbobenzoxy-LeuLeu-Leucinal), a membrane-permeable peptide aldehyde [11],
effectively blocks the proteolytic activity of the proteosome
complex. When the cell senses the buildup of aberrant
proteins, its mitochondria begin to accumulate Ca++ , resulting in cytochrome c release and mitochondrial dysfunction
[12], which initiates PARP mediated cell death. Aberrant
proteins also initiate ER stress, as indicated by the induction
of CCAAT/enhancer-binding protein homologous protein
(CHOP) expression [13], and the unfolded protein response,
which leads to apoptosis.
In eukaryotic cells, the UPS is the main system that
degrades misfolded proteins exporting from the ER. However, ER stress, as part of the UPR pathway, can also activate
autophagy by conjugation of LC3 (microtubule associated
protein 1 light chain 3) to membrane lipids [14].
In many neuronal cell types and in the Central Nervous
System (CNS), proteasome inhibition causes mitochondrial
dysfunction, reduces glutathione levels, and increases generation of free radicals [15]. This leads to the elevation
of intracellular reactive oxygen species (ROS), resulting in
oxidative stress. Increase in the levels of free radicals increases
protein oxidation and further compromises proteasomal
degradative capacity. By these activities, oxidative stress may
fuel a vicious cycle that links mitochondrial dysfunction to
proteasomal inhibition and autophagy, both of which lead to
neurodegeneration [16].
Previous research has shown that antioxidant treatment
of PD patients can mitigate neuronal damage by uncoupling
mitochondrial damage from cellular oxidative stress in neurotoxicity and autophagy [16]. N-Acetylcysteine (NAC) is a
membrane-permeable antioxidant and free radical scavenger
that increases intracellular GSH by delivering cysteine to
cells and acting as a precursor for glutathione synthesis.
Its neuroprotective effects have been established in animal
models and cell culture studies of non-PD neurodegenerative
disease [16–19], and it has been successfully used for the
treatment of psychiatric disorders [20]. In the present study,
we assessed the individual and combined efficacy of two
classes of agents, an antioxidant and a neurotrophic factor, for
their ability to prevent cell death in cultured neuronal cells
following UPS impairment with the proteasome inhibitor
MG132. NAC was chosen as the antioxidative component and
insulin-like growth factor-1 (IGF-1) was chosen as the neurotrophic component. The latter compound is a 70-aminoacid-long polypeptide with known neurotrophic, neurogenic,
neuroprotective, and antiapoptotic effects, and it is essential

Parkinson’s Disease
for the development of the nervous system where it regulates
cell growth, differentiation, and survival of neurons and their
supporting cells [21, 22]. The primary mechanism by which
IGF-1 elicits these efforts is the PI3/AKT pathway [23]. To
the best of our knowledge, NAC and IGF-1 have not been
tested for their ability, in combination, to protect proteasomeinhibited human dopaminergic cell lines.

2. Materials and Methods
2.1. Reagents. N-Acetylcysteine, IGF-1, MG132, MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide],
and 3-methyladenine (3-MA) were purchased from SigmaAldrich (St. Louis, MO, USA) and Hoechst 33342 and
2 ,7 -dichlorodihydrofluorescein diacetate (DCFDA) from
Life Technologies (Eugene, OR, USA).
2.2. Cell Culture. Human SH-SY5Y cells and cell culture
medium were purchased from the American Type Culture
Collection (Manassas, VA, USA). The cells were cultured
at 5% CO2 at 37∘ C in EMEM: Ham’s F-12K medium
(1 : 1) containing 10% fetal bovine serum (FBS), penicillin
(100 units/mL), and streptomycin (100 𝜇g/mL). The cells were
subcultured weekly in 60 mm or 100 mm cell culture dishes
and used for experiments at 85–90% confluence. The culture
medium was changed every 2-3 days. For Hoechst 33342
nucleic acid staining, cells were grown in 4-well chamber
slides.
2.3. Inhibitor Treatments. The proteasome inhibitor MG132
was used to induce cytotoxicity in SH-SY5Y cultures. DMSO
was used as a control vehicle, the final concentration of
which was less than 0.1% in the cell culture medium. IGF1 was suspended in sterile water, and NAC was dissolved in
the culture medium. In neuroprotection experiments, SHSY5Y cells were pretreated with IGF-1 (20 nM) and NAC
(3 mM) alone, or with a combination of the two at the
same concentration, for 18 h. The cells were then treated
with MG132 (5 𝜇M) for 24 h, unless otherwise indicated. To
avoid any reversible action, the inhibitors were maintained
throughout the duration of the experiment.
2.4. Cell Viability Assays. The cells were incubated in 24well dishes, and cell viability data was determined using
MTT assays, measuring the conversion of MTT [3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
into formazan, as described in the previous study [24].
Thereafter, cells were treated with fresh media containing
0.25 mg/mL MTT for 2 h at 37∘ C. The medium was then
removed and the purple formazan salt was solubilized with
equal amounts of DMSO, and 100 𝜇L of each sample was
transferred to 96-well plates. The spectrophotometric densities were determined at absorption of 490 nm. At least 6
replicates of each treatment were used.
2.5. Immunoblot Assay. Changes in the amounts of protein
expression were measured by Western blot analysis. For
Western blotting, the cells were lysed in ice-cold RIPA lysis
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2.6. Cell Apoptotic Determination. An immunoblot assay was
performed to assess PARP and caspase 3 cleavage for cells in
the control and pretreated cultures. Nuclear morphological
changes were assessed using Hoechst 33342 dye and visualized under a confocal microscope. For staining assays with
the Hoechst 33342 nuclear dye, cells were cultured on glassbottom dishes. After treatments, the cells were fixed with
3.7% paraformaldehyde for 20 min, washed with PBS three
times, and stained with 1 𝜇g/mL solution for 30 min. Stained
cells were mounted using Vectashield Mounting Medium for
Fluorescence (Vector Laboratories, Burlingame, CA, USA)
and imaged with an Olympus FV1000 confocal microscope
utilizing Olympus FV10-ASW3.1 software.
2.7. Oxidative Stress Assay. ROS production was detected
using a cell-permeant fluorescent dye, 2 ,7 -dichlorodihydrofluorescein diacetate (DCFDA), as previously described [25].
After treatment, cells were loaded with DCFDA (10 𝜇M) and
incubated for 30 min. The cells were then rinsed with PBS
and fluorescence was measured immediately in a fluorescence
microplate reader (SpectraMax, Molecular Devices). Wavelengths for excitation and emission were 485 and 520 nm,
respectively.
2.8. Measurement of Reduced Glutathione. GSH levels were
determined as previously described by Kamencic et al.
2000 [26]. Cells were cultured at 37∘ C in the presence or
absence of the treatment reagents indicated above, washed
with PBS, and incubated with monochlorobimane (MCB,
40 𝜇mol/L) in the dark for 30 min at 37∘ C. After two washes
with PBS, fluorescence was measured by spectrofluorophotometer (SpectraMax, Molecular Devices), with excitation
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buffer containing freshly added protease and phosphatase
inhibitors. The lysates were clarified by centrifugation at 4∘ C
for 20 min at 13,000 rpm, and their protein concentrations
were measured with a BCA Protein Assay Kit (Pierce,
Rockford, IL, USA). Equal amounts of the protein samples
(25–30 𝜇g) were loaded and separated on 10% or 4–20% gradient polyacrylamide gels (Bio-Rad Laboratories, Hercules,
CA, USA). The proteins were transferred to nitrocellulose
membranes and blocked for either 1 h at room temperature
or overnight at 4∘ C with Tris buffered saline containing 0.1%
Tween 20 (TBST, pH 7.4) and 5% (w/v) skimmed dried milk.
Anti-PARP, anti-cleaved caspase 3, anti-CHOP and antiLC3B antibodies were purchased from Cell Signaling (Beverly, MA, USA). Anti-ubiquitin antibody was obtained from
Santa Cruz Biotechnology (Dallas, TX, USA). Anti 𝛽-actin
was acquired from Sigma-Aldrich (St. Louis, MO, USA). The
blotted membranes were incubated with primary antibodies
for 1 h at room temperature or overnight at 4∘ C. They
were then washed and incubated for 1 h with appropriate horseradish peroxidase-conjugated secondary antibodies.
The protein bands were revealed using enhanced chemiluminescent (ECL) method, according to the manufacturer’s
instructions. Quantification of band densities was analyzed
using one-way analysis of variance and Tukey’s comparison
test, using the Instat biostatistic program (GraphPad Software).
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Figure 1: Pretreatment with IGF-1 and NAC increases cell viability
after MG132 treatment. Cells were pretreated with vehicle (DMSO),
IGF-1 (I), NAC (N), or both (I + N) for 18 h followed by the addition
of MG132 (MG) (5 𝜇M) for 24 h. Cell viability was determined
by MTT assay as described in the Materials and Methods. The
results are expressed as percentage means ± SEM of control and are
representative of three independent experiments with five replicates.
Level of significance is denoted as ∗ 𝑝 ≤ 0.05 and ∗∗ 𝑝 ≤ 0.005.

and emission wavelengths of 405 and 510 nm, respectively.
Samples were assayed in triplicate.
2.9. Data Analysis. Our data was analyzed using one-way
analysis of variance and Tukey comparison test, using GraphPad statistical software. Data is presented as the mean ± SEM
of at least three independent experiments. In the figures,
asterisks indicate the degree of significance for different
treated cell cultures when compared to treatment controls
or as specifically mentioned (∗ 𝑝 ≤ 0.05–0.01, ∗∗ 𝑝 ≤ 0.005,
resp.).

3. Results
3.1. The Combination of IGF-1 and NAC Increases SH-SY5Y
Cells Protection against MG132 Induced Toxicity. The cells
were treated either with 3 mM NAC or 20 nM IGF-1 or with
the two in combination for 18 hours, followed by exposure
to MG132 (5 𝜇M) for 24 hours. The selection of dose and
duration of exposure for IGF-1 and NAC were based on
previously reported results [24] and preliminary dose effect
data showing maximum protection, respectively.
As shown in Figure 1, MG132 treated cells showed
significant reduction of cell viability, after 24-hour incubation, relative to untreated control cells (𝑝 < 0.005). In
contrast, pretreatment of the cells with IGF-1 or NAC reduced
MG132 induced cytotoxicity and promoted cell survival by
15.7% ± 2.26% and 7.82% ± 1.41%, respectively, compared
to MG132 treated cells. Combined administration of NAC
and IGF-1 produced the best protection of SH-SY5Y cells as
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evidenced by a 25.4% increase in cell viability (𝑝 < 0.005)
(Figure 1).
3.2. The Combination of IGF-1 and NAC Attenuates MG132
Induced Apoptosis in SH-SY5Y Cells. Proteasome inhibition
is known to be associated with induction of apoptosis [12].
To confirm and expand on the results from Figure 1, which
suggested that NAC/IGF-1 are more effective together, Western blot analysis was used to detect two apoptotic markers,
PARP cleavage and cleaved caspase 3 in treated and untreated
cells. As shown in Figures 2(a) and 2(b), exposure of SHSY5Y cells to MG132 for 24 hours resulted in significantly
enhanced levels of both cleaved PARP and cleaved caspase
3 in comparison to control cells (𝑝 < 0.005). However,
pretreatment of the cells with NAC or IGF-1 significantly
reduced levels of both the markers (𝑝 < 0.05) in comparison
to unprotected cells exposed to MG132. In agreement with
Figure 1, the cells pretreated with both NAC and IGF-1 exerted
complete protection against MG132 induced toxicity (𝑝 <
0.005) (Figures 2(a) and 2(b)).
In addition to the above apoptotic markers, we compared
nuclear morphological changes between unprotected and
protected cells. To visualize nuclear morphology, cells were
stained with the DNA dye Hoechst 33342. Since lower doses
of MG132, such as 5 𝜇M, do not cause evident chromatin
condensation after 24 hours, a higher MG132 concentration
of 10 𝜇M was employed. Cells incubated with MG132 alone
exhibited extensive chromatin condensation and nuclear
fragmentation, whereas relatively few of these structures were
present in cells pretreated with NAC or IGF-1 alone. Furthermore, cotreatment with NAC and IGF-1 nearly completely
prevented the appearance of apoptotic bodies in the cells
(Figures 2(c) and 2(d)).
3.3. NAC and IGF-1 Alone or in Combination Attenuates
MG132 Induced Reactive Oxygen Species (ROS) Generation
and Depletion of Cellular GSH. SH-SY5Y cells were untreated
or treated with NAC or IGF-1 alone or together for 18 hours
followed by addition of 5 𝜇M MG132 for an additional 24
hours as indicated in Figure 3. Thereafter the cells from all
treatments were incubated with 10 𝜇M DCFDA or 40 𝜇M
monochlorobimane (MCB) for 30 minutes, and their relative
fluorescence was then measured. The results demonstrate that
MG132 significantly reduced total intracellular GSH content
(𝑝 < 0.05). However, MG132 induced depletion of GSH was
attenuated by pretreatment with NAC or IGF-1, alone or in
combination (Figure 3(a)). It was further noted that DCFDA
intensity was elevated in cells treated with MG132 compared
to the control. However, MG132 induced ROS production was
significantly suppressed in cells pretreated with NAC (𝑝 <
0.05) or IGF-1 (𝑝 < 0.005) alone and was further reduced by
the two together (𝑝 < 0.005) (Figure 3(a)).
3.4. Pretreatment with NAC and IGF-1 Does Not Reduce
MG132 Induced Protein Ubiquitination, but It Inhibits Proteasome-Induced Autophagy. Proteasomal inhibition causes
accumulation of ubiquitinated proteins in large amounts
[24, 27] irrespective of protection afforded by pretreatment
with retinoic acid or IGF-1. Therefore, in the present study
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we sought to determine whether NAC, used alone or in
combination with IGF-1, can reduce protein ubiquitination
or affect autophagy, which is the default protein disposal
pathway used by neurons whose proteasomes are dysfunctional [8]. Figure 4(a) confirms our previous finding from
studies with other protective agents showing that proteasome
inhibitor-treated cells contain significantly increased levels of
ubiquitinated protein regardless of the presence or absence of
NAC or IGF-1. To determine whether autophagy is deployed
in NAC/IGF-1 protected cells, we tested challenged cells,
protected challenged cells, and untreated cells for their levels
of the autophagosomal membrane (lipid-bound) form of
LC3. This marker is a mammalian homolog of the autophagyrelated gene 8 in yeast [28] and is one of the most reliable
markers by which to monitor autophagy [29]. Figures 4(a)
and 4(b) show that MG132-treated cells contain increased levels of lipid-bound LC3 (𝑝 < 0.005). Though not significant,
a partial reduction in LC3 level resulted in cells pretreated
with NAC or IGF-1 alone. However, cotreatment with NAC
and IGF-1 reversed MG132 induced expression of LC3 (𝑝 <
0.005). Furthermore, compared to treatment with either IGF1 or NAC alone, cotreatment with NAC and IGF-1, LC3-II
was further decreased (𝑝 < 0.05). These results identify
autophagy as a central player in protein quality control, and in
the subsequent cell death versus cell survival, of NAC/IGF-1
protected cells.
3.5. Cotreatment with NAC and IGF-1 Attenuates Endoplasmic Reticulum Stress. The involvement of endoplasmic
reticulum (ER) stress in PD neuronal damage has been
well-established [30, 31]. Suppression of proteasome activity induces the accumulation of CCAAT/enhancer-binding
protein homologous protein (CHOP) in the ER [32]. To
assess the degree to which ER stress participates in MG132
induced cell death of SH-SY5Y cells, we evaluated the effect
of NAC and IGF-1 on expression of CHOP. Figure 5(a)
shows that exposure of the cells to MG132 results in the
expression of CHOP. However, treatment of the cells with
NAC, IGF-1, or both NAC and IGF-1 prior to MG132 exposure
reduced its expression. In fact, cotreatment with both agents
prior to MG132 exposure reduced the MG132 induced stress
response to basal levels seen in the control. Densitometry
analysis revealed CHOP levels significantly increased 14.5 ±
3 times (𝑝 < 0.05) in MG132 treated cells compared to the
control, whereas the levels significantly decreased in cells
pretreated with IGF-1, NAC, or both, respectively (𝑝 < 0.05)
(Figure 5(b)).
3.6. Autophagy Inhibition Suppresses Apoptosis in SH-SY5Y
Cells Treated with MG132. To investigate the contribution
of autophagy to apoptosis, cell cultures were set up as
described in Figures 1–5, but in the presence or absence of the
autophagy inhibitor 3-methyladenine (3-MA), which blocks
autophagosome formation via phosphatidylinositol 3-kinase
(PI3K). As shown in Figure 6, MG132 induced apoptosis is
indicated by the expression of cleaved PARP (Figure 6(b))
and cleaved caspase 3 (Figure 6(c)); however, when cells were
treated with the autophagy inhibitor 3-MA, both PARP and
caspase 3 cleavage were dramatically reduced, suggesting that
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Figure 2: IGF-1 and NAC repress MG132 induced apoptosis. (a) Western blot analysis for two apoptotic markers: cleaved PARP and cleaved
caspase 3. Results are representative of three independent experiments. (b) Densitometric analysis from three separate experiments. 𝛽-Actin
served as the loading control. (c) IGF-1 and NAC prevent MG132 induced nuclear morphological changes. Cells were pretreated with IGF-1
(I), NAC (N), or both (I + N) for 18 h, followed by treatment with MG132 (MG) (10 𝜇M) for 24 h, as indicated. The treated cells were then
stained with the Hoechst reagent. Nuclear morphological changes were imaged using a confocal fluorescence microscope (arrows denote
apoptotic nuclei). The photomicrographs shown are representative of three repeated experiments. (d) Quantification of cells with abnormal
nuclei. Values are mean ± SEM (𝑛 = 3) (∗ 𝑝 ≤ 0.05, ∗∗ 𝑝 ≤ 0.005).
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Figure 3: IGF-1 and NAC increase GSH production and reduce MG132 induced ROS generation in SH-SY5Y cells. Cell cultures were treated
with NAC or IGF-1, separately or together, as described for Figure 1, followed by MG132 (5 𝜇M). (a) Glutathione assay results for the control
and treated cells versus MG132 treated cells only. (b) Intracellular ROS levels. Level of significance is denoted as ∗ 𝑝 ≤ 0.05 and ∗∗ 𝑝 ≤ 0.005.
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autophagy is partially involved in MG132 induced apoptotic
cell death of SH-SY5Y cells.

4. Discussion
The efficacy of combination therapy depends on the use
of drugs with different but complimentary mechanisms of
action. Since PD pathology is driven by multiple factors,
concomitant neuroprotective treatments are likely to be
more effective than treatment with a single agent. Some
well-established anomalies associated with PD are aberrant
protein homeostasis, oxidative stress, excitotoxicity, and
inflammatory processes, which induce apoptosis in the nigral
dopaminergic neurons [33, 34]. Therefore, agents that could
prevent these events could be neuroprotective, and their
effect on disease progression, or even prevention, may be
substantially enhanced when combination therapies are used.
The present study evaluates the neuroprotective potential
of monotherapy and combination therapy of NAC and IGF-1
on proteasome dysfunction-induced neurotoxicity in human
neuroblastoma SH-SY5Y cells by exploring the relationship
between oxidative stress, ER stress, autophagy, and apoptotic
cell death following proteasome inhibition. The neuroprotective effect of NAC is mainly due to its ROS scavenging
potential and its maintenance of cellular GSH [16], whereas
IGF-1 protects neurons against cell death via intracellular pathways involving PI3k/Akt-mediated phosphorylation

FKHRL1 (a subclass of winged-helix family of transcription
factors) [24, 35, 36] and inhibition of oxidative stress [37, 38].
A combination of both agents may broaden the spectrum
of protection by acting on multiple mechanisms involving
oxidative stress and multiple antiapoptotic signaling pathways.
We find that MG132 treatment substantially reduced the
viability of SH-SY5Y cells. Evaluation of various parameters
such as nuclear condensation and fragmentation and activation of caspases and PARP cleavage clearly indicated a
pronounced proapoptotic effect stimulated by MG132. This
cell death pathway involved ROS formation, GSH depletion,
ER stress, and induction of autophagy. This study confirms,
once again, that treatment of SH-SY5Y cells with MG132 can
be a reliable model that replicates all the neuropathological
abnormalities of PD, such as mitochondrial dysfunction,
oxidative stress, and loss of proteasomal function [15].
While MG132 had a significant cytotoxic effect on SHSY5Y cells as demonstrated by MTT assay, pretreatment
with either NAC or IGF-1 protected cells from MG132
induced damage. Cotreatment with both agents resulted in
a striking increase in protection. This effect may be the
result of mitigating apoptosis, enhancing intracellular GSH,
reducing ROS, and/or attenuating ER stress and autophagy.
The antiapoptotic potential of NAC has been established both
in vitro [12, 39] and in vivo [40]. Although the protective effect
of NAC against MG132 induced cell death has been reported
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in various cell lines including neuronal cell lines, a similar in
vitro dose of NAC did not attenuate the detrimental effect
of MG132 in N27 cells [41]. This conflicting result may be
attributed to the characteristic of the cell line used.
An important regulatory element in the protein ubiquitination pathway is the redox state of cellular GSH and
its depletion may induce cell death [42]. MG132 induced
cell death was preceded by pronounced depletion of GSH.
Pretreatment of MG132 treated cells with either NAC, IGF1, or both exerted similar effect of restoring the GSH levels.
By acting as precursor to GSH and enhancing its biosynthesis
NAC and IGF-1 maintain the reduced GSH content, respectively [43].
Pretreatment with NAC, IGF-1, or both significantly
counteracted MG132 induced production of ROS. NAC acted
as a direct scavenger and reduced more ROS in comparison to the individual treatments. Production of ROS is an
intermediate step in MG132 induced apoptosis [44, 45] and
thus protection of cells by NAC and IGF-1 pretreatment
strongly highlights the key role of cellular redox status in

the mechanism of neuroprotection by these two agents.
Several lines of evidence also indicate the involvement of
ROS and cellular redox status in the regulation of autophagy
[46]. When we asked whether suppression of autophagy
distinguishes protected, surviving MG132-treated cells from
unprotected ones, we found that attenuation of autophagy
is a defining feature of NAC/IGF-1-treated cells that survive
MG132 challenge. While partial reduction of the autophagy
marker LC3-II was detected in cells pretreated with either
NAC or IGF-1, cotreatment of cells with both completely
prevented MG132 induced autophagy, with the protective
effects of either drug or both drugs being correlated with the
degree to which the cells are protected.
Autophagy and ER stress are intimately related [47] and
autophagy is accelerated in cells under ER stress [14]. In fact,
impairment of autophagy by NAC or IGF-1 has been previously reported [16, 48]. Thus, the enhanced effect of NAC
and IGF-1 demonstrates that combination treatment with
these two agents has potential as a powerful therapeutic strategy against proteasome dysfunction-induced neurotoxicity.
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Furthermore, by demonstrating that autophagy plays a role
in NAC and IGF-1 neural protection, our study implies that
autophagy is a potential therapeutic target for PD treatment.
Despite considerable recent advances, it is still debated
whether autophagy is either a cytoprotective response triggered by cells to survive cellular stress or a cytotoxic phenomenon associated with cell death [49]. Dysregulation of
autophagy has been described in neurodegenerative diseases
including PD [50, 51]. However, depending upon the cellular
milieu, autophagy may promote cell survival or death [52,
53]. To assess the effect of autophagy in our system from a
different angle, we measured MG132 induced cell death in
the presence of an inhibitor of autophagy, 3-methyladenine
(3-MA). Treatment with 3-MA partially blocked MG132
induced apoptosis (Figure 5), suggesting the involvement
of autophagy in MG132-mediated neurotoxicity within SHSY5Y cells. In summary, inhibition of proteasome by MG132
increases the aggregation of damaged and misfolded proteins.
Acting as the primary cytotoxic stressor, the aggregated proteins then trigger downstream ROS accumulation, ER stress,
and cell death via the caspase cascade and/or autophagy (Figure 7). The complete inhibition of apoptosis by the NAC and
IGF-1, which only partially reduces LC3-II, underscores the
involvement of multiple protective pathways involving ROS
formation and GSH depletion and ER stress and autophagy.

5. Conclusions
Proteasome inhibition in SH-SY5Y cells triggers apoptotic
cell death. A drug combination therapy comprised of NAC
and IGF-1 completely alleviates cytotoxicity associated with
proteasome dysfunction. The neuroprotective effect relies on
modulation of multiple pathways associated with apoptosis,
which include reducing ROS, GSH depletion, lowering ER
stress, and preventing autophagy (Figure 7). Thus a combination therapy employing a neurotrophic factor (IGF-1)
and a free radical scavenger (NAC) may provide a novel
and promising therapeutic strategy for UPS dysfunctionmediated neurocell degeneration.
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